Terms: = Colorectal cancer AND TIMP1, CLGI, EPA, EPO, HCI, TIMP, TIMP-1 AND Treatment
144 results:
1. Urolithin A affects cellular migration and modulates matrix metalloproteinase expression in colorectal cancer cells.
El-Wetidy MS; Rady MI; Rady I; Helal H
Cell Biochem Funct; 2024 Apr; 42(3):e4019. PubMed ID: 38622949
[TBL] [Abstract] [Full Text] [Related]
2. Constructing a personalized prognostic risk model for colorectal cancer using machine learning and multi-omics approach based on epithelial-mesenchymal transition-related genes.
Zhang S; Fan W; He D
J Gene Med; 2024 Jan; 26(1):e3660. PubMed ID: 38282145
[TBL] [Abstract] [Full Text] [Related]
3. The Salmon Oil OmeGo Reduces Viability of colorectal cancer Cells and Potentiates the Anti-cancer Effect of 5-FU.
Pettersen CHH; Samdal H; Sætrom P; Wibe A; Hermansen E; Schønberg SA
Mar Drugs; 2023 Dec; 21(12):. PubMed ID: 38132957
[TBL] [Abstract] [Full Text] [Related]
4. Integration of single-cell transcriptomics and epigenetic analysis reveals enhancer-controlled timp1 as a regulator of ferroptosis in colorectal cancer.
Li M; Ni QY; Yu SY
Genes Genomics; 2024 Jan; 46(1):121-133. PubMed ID: 38032469
[TBL] [Abstract] [Full Text] [Related]
5. Randomised, placebo-controlled, phase 3 trial of the effect of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid (epa) on colorectal cancer recurrence and survival after surgery for resectable liver metastases: epa for Metastasis Trial 2 (EMT2) study protocol.
Hull MA; Ow PL; Ruddock S; Brend T; Smith AF; Marshall H; Song M; Chan AT; Garrett WS; Yilmaz O; Drew DA; Collinson F; Cockbain AJ; Jones R; Loadman PM; Hall PS; Moriarty C; Cairns DA; Toogood GJ
BMJ Open; 2023 Nov; 13(11):e077427. PubMed ID: 38030258
[TBL] [Abstract] [Full Text] [Related]
6. Exploration of an Prognostic Signature Related to Endoplasmic Reticulum Stress in colorectal Adenocarcinoma and Their Response Targeting Immunotherapy.
Xu Y; Xie YM; Sun WS; Zi R; Lu HQ; Xiao L; Gong KM; Guo SK
Technol Cancer Res Treat; 2023; 22():15330338231212073. PubMed ID: 37920989
[No Abstract] [Full Text] [Related]
7. The effect of aspirin and eicosapentaenoic acid on urinary biomarkers of prostaglandin E
Sun G; Fuller H; Fenton H; Race AD; Downing A; Williams EA; Rees CJ; Brown LC; Loadman PM; Hull MA
Int J Cancer; 2024 Mar; 154(5):873-885. PubMed ID: 37855394
[TBL] [Abstract] [Full Text] [Related]
8. Polymorphisms in Cyclooxygenase, Lipoxygenase, and TP53 Genes Predict colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial.
Davies JR; Mell T; Fuller H; Harland M; Saleh RNM; Race AD; Rees CJ; Brown LC; Loadman PM; Downing A; Minihane AM; Williams EA; Hull MA
Cancer Prev Res (Phila); 2023 Nov; 16(11):621-629. PubMed ID: 37756582
[TBL] [Abstract] [Full Text] [Related]
9. The anoikis-related gene signature predicts survival accurately in colon adenocarcinoma.
Hu G; Li J; Zeng Y; Liu L; Yu Z; Qi X; Liu K; Yao H
Sci Rep; 2023 Aug; 13(1):13919. PubMed ID: 37626132
[TBL] [Abstract] [Full Text] [Related]
10. Construction and validation of a prognostic model for colon adenocarcinoma based on bile acid metabolism-related genes.
Luo Q; Zhou P; Chang S; Huang Z; Zeng X
Sci Rep; 2023 Aug; 13(1):12728. PubMed ID: 37543674
[TBL] [Abstract] [Full Text] [Related]
11. colorectal polyp outcomes after participation in the seAFOod polyp prevention trial: Evidence of rebound elevated colorectal polyp risk after short-term aspirin use.
Downing A; Fenton H; Nickerson C; Loadman PM; Williams EA; Rees CJ; Brown LC; Morris EJA; Hull MA
Aliment Pharmacol Ther; 2023 Sep; 58(6):562-572. PubMed ID: 37518954
[TBL] [Abstract] [Full Text] [Related]
12. The Potential of DHA as cancer Therapy Strategies: A Narrative Review of In Vitro Cytotoxicity Trials.
de Freitas Rodrigues J; Philippsen HK; Dolabela MF; Nagamachi CY; Pieczarka JC
Nutrients; 2023 Apr; 15(8):. PubMed ID: 37111226
[TBL] [Abstract] [Full Text] [Related]
13. Plasma and rectal mucosal oxylipin levels during aspirin and eicosapentaenoic acid treatment in the seAFOod polyp prevention trial.
Fuller H; Race AD; Fenton H; Burke L; Downing A; Williams EA; Rees CJ; Brown LC; Loadman PM; Hull MA
Prostaglandins Leukot Essent Fatty Acids; 2023 May; 192():102570. PubMed ID: 37003144
[TBL] [Abstract] [Full Text] [Related]
14. An epithelial-mesenchymal transition-related mRNA signature associated with the prognosis, immune infiltration and therapeutic response of colon adenocarcinoma.
Zhang Y; Li Y; Zuo Z; Li T; An Y; Zhang W
Pathol Oncol Res; 2023; 29():1611016. PubMed ID: 36910014
[No Abstract] [Full Text] [Related]
15. A prospective cohort study of timp1 as prognostic biomarker in gastric and colon cancer.
Macedo FC; Cunha N; Pereira TC; Soares RF; Monteiro AR; Bonito N; Valido F; Sousa G
Chin Clin Oncol; 2022 Dec; 11(6):43. PubMed ID: 36509552
[TBL] [Abstract] [Full Text] [Related]
16.
Wijler LA; Dijk FJ; Quirindongo H; Raats DAE; Dorresteijn B; Furber MJW; May AM; Kranenburg O; van Dijk M
Oncotarget; 2022 Oct; 13():1094-1108. PubMed ID: 36242541
[TBL] [Abstract] [Full Text] [Related]
17. The differential cancer growth associated with anaesthetics in a cancer xenograft model of mice: mechanisms and implications of postoperative cancer recurrence.
Iwasaki M; Zhao H; Hu C; Saito J; Wu L; Sherwin A; Ishikawa M; Sakamoto A; Buggy D; Ma D
Cell Biol Toxicol; 2023 Aug; 39(4):1561-1575. PubMed ID: 35953652
[TBL] [Abstract] [Full Text] [Related]
18. Cabozantinib with or without Panitumumab for RAS wild-type metastatic colorectal cancer: impact of MET amplification on clinical outcomes and circulating biomarkers.
Jia J; Howard L; Liu Y; Starr MD; Brady JC; Niedzwiecki D; Strickler JH; Nixon AB
Cancer Chemother Pharmacol; 2022 Mar; 89(3):413-422. PubMed ID: 35171350
[TBL] [Abstract] [Full Text] [Related]
19. Fish Oil, Plant Polyphenols, and Their Combinations Have No Tumor Growth Promoting Effects on Human Lung and Colon Carcinoma Xenograft Mice.
Das T; Dvoretskiy S; Chen C; Luo M; Pereira SL
J Diet Suppl; 2023; 20(3):459-474. PubMed ID: 34983294
[TBL] [Abstract] [Full Text] [Related]
20. Plasma Protein Biomarkers in Advanced or Metastatic colorectal cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance).
Nixon AB; Sibley AB; Liu Y; Hatch AJ; Jiang C; Mulkey F; Starr MD; Brady JC; Niedzwiecki D; Venook AP; Baez-Diaz L; Lenz HJ; O'Neil BH; Innocenti F; Meyerhardt JA; O'Reilly EM; Owzar K; Hurwitz HI
Clin Cancer Res; 2022 Jul; 28(13):2779-2788. PubMed ID: 34965954
[TBL] [Abstract] [Full Text] [Related]
[Next]
